Quarterly report pursuant to Section 13 or 15(d)

Other current assets (Tables)

v3.24.1.1.u2
Other current assets (Tables)
3 Months Ended
Mar. 31, 2024
Other current assets  
Summary of other current assets

​

​

​

​

​

​

​

​

​

​

March 31, 

​

December 31, 

​

    

2024

​

2023

Research and development credits receivable

 

$

18,697

​

$

46,098

Prepayments

 

​

9,854

​

​

9,954

Clinical materials

 

​

1,668

​

​

1,329

VAT receivable

​

​

1,791

​

​

—

Other current assets

 

​

2,837

​

​

2,412

​

​

$

34,847

​

$

59,793